Sierra Sciences

Sierra Sciences is a pioneering, private-stage biotech firm dedicated to combating aging as a disease through telomere lengthening. Founded and led by Dr. Bill Andrews, a key figure in telomerase research, the company's core strategy is to discover small molecule compounds that activate the telomerase enzyme. While the vision is ambitious, aiming for a global therapeutic impact, the company appears to be in a pre-clinical, pre-revenue research phase, relying on public engagement and support to fund its long-term scientific goals. Its work sits at the controversial intersection of biogerontology and speculative therapeutics.

High-throughput screening platform for small molecule telomerase activators aimed at inducing telomerase expression to lengthen telomeres.

Sierra Sciences operates in the competitive longevity biotech space but is niche in its exclusive focus on telomerase activation. It faces competition from well-funded companies pursuing senolytics (e.g., Unity Biotechnology), mTOR inhibition, and epigenetic reprogramming. Its greatest competition may be the broader scientific skepticism towards its single-mechanism, cure-all approach.